Lubiprostone: Uses, Safety and Drug Interactions

Lubiprostone: uses, safety and drug interactions

Overview: Lubiprostone increases intestinal fluid secretion and helps stool passage. The United States label reviewed here covers adult chronic idiopathic constipation, selected opioid-induced constipation in adults with chronic non-cancer pain, and irritable bowel syndrome with constipation in women aged eighteen or older. These are distinct indications with different prescribing regimens, not interchangeable reasons to use the same capsule strength.

Uses and formulation: It is an oral soft capsule taken with food and water and swallowed whole. Taking it with food can reduce nausea. Clinicians should periodically review whether it is still needed. Possible mechanical bowel obstruction must be assessed before treatment, and the medicine is contraindicated when obstruction is known or suspected. Severe diarrhoea is also a reason to seek medical advice rather than continuing without review.

Safety: Nausea and diarrhoea are common adverse effects. Fainting, low blood pressure and episodes of shortness of breath have also been reported, sometimes soon after a dose. Diarrhoea or vomiting may add to the risk of fainting. Seek prompt assessment for these symptoms or an allergic reaction. Pregnancy data in humans are insufficient. During breastfeeding, the prescriber should assess benefits and possible risks, and the infant should be monitored for diarrhoea.

Drug interactions: Postmarketing reports describe low blood pressure or fainting in some patients also taking medicines that lower blood pressure. This is a precaution requiring individual assessment, not proof of a direct metabolic interaction with every blood pressure medicine. Methadone can interfere with lubiprostone action in laboratory studies, and effectiveness for methadone-associated constipation has not been established. That specific finding should not be automatically extended to unrelated opioids.

Sources

• Lubiprostone oral capsules, Par Health USA authorized generic, US Prescribing Information
• WHO Collaborating Centre: ATC/DDD Index A06AX

This page provides an English summary of the cited sources. Source check: 30 October 2026. This date records a source check, not a clinical review by a doctor or pharmacist. Follow the current leaflet for your product and seek professional advice for personal treatment.